The Modeling of Recurrent and Metastatic Colorectal Cancer Growth Kinetics to Assess Chemotherapeutic Treatment Efficacy

One of the major problems in drug therapy administration in cancer patients is the lack of information on sensitivity of tumor cells to chemotherapeutic agents (initial uncertainty). A dividing cancer cell is known to be the primary point of chemotherapeutic agent application. The authors have developed a mathematical model, where tumor growth is considered as a complex balance between cancer cell division and death. There have been studied the combinations of parameters of proliferative activity of cells and cell death, when it is possible to reach maximum effect in cytostatic treatment. The efficacy of adjuvant chemotherapy in the prevention of colorectal cancer recurrences and metastases has been analyzed.

1. Cassidy L.D. Basic concepts of statistical analysis for surgical research. J Surg Res 2005; 128(2): 199–206, http://dx.doi.org/10.1016/j.jss.2005.07.005.
2. Davis C.S. Statistical methods of the analysis of repeated measurements. New York: Springer-Verlag; 2002; 744 p.
3. Katz M.H. Multivariable analysis: a primer for readers of medical research. Ann Intern Med 2003; 138(8): 644–650, http://dx.doi.org/10.7326/0003-4819-138-8-200304150-00012.
4. Bland J.M., Altman D.G. Survival probabilities (The Kaplan–Meyer method). BMJ 1998; 317(7172): 1572, http://dx.doi.org/10.1136/bmj.317.7172.1572.
5. Royston P., Parmar M.K., Altman D.G. Visualizing length of survival in time-to-event studies: a complement to Kaplan–Meier plots. J Natl Cancer Inst 2008; 100(2): 92–97, http://dx.doi.org/10.1093/jnci/djm265.
6. Adlard J.W., Richman S.D., Seymour M.T., Quirke P. Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol 2002; 3(2): 75–82, http://dx.doi.org/10.1016/S1470-2045(02)00648-4.
7. Folprecht G., Köhne C.H. The role of new agents in the treatment of colorectal cancer. Oncology 2004; 66(1): 1–17, http://dx.doi.org/10.1159/000076329.
8. Fuchs C.S., Marshall J.L., Mitchell E., et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol 2007; 25(30): 4779–4786, http://dx.doi.org/10.1200/JCO.2007.11.3357.
9. Moiseenko V.M. “Estestvennaya istoriya” rosta raka molochnoy zhelezy. V kn.: Prakticheskaya onkologiya: izbrannye lektsii [Natural history of breast cancer growth. In: Practical oncology: selected lectures]. Pod red. Tyulyandina S.A., Moiseenko V.M. [Tyulyandin S.A., Moiseenko V.M. (editors)]. Moscow, 2004; p. 22.

Bazanov К.V., Kuznetsov S.S., Terentiev I.G. The Modeling of Recurrent and Metastatic Colorectal Cancer Growth Kinetics to Assess Chemotherapeutic Treatment Efficacy. Sovremennye tehnologii v medicine 2014; 6(4): 85